A Pennsylvania overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
34.2% of Pennsylvania adults have obesity, per the CDC's 2024 BRFSS wave (95% CI 32.0–36.5%, n=3,251) 3. Another 34.7% are overweight, so 68.9% of the state's adults sit above a healthy weight range 3.
Pennsylvania's Medicaid rules for these drugs changed on March 2, 2026, and the new bulletin is precise about which diagnoses open the door.
No. Pennsylvania Medical Assistance, both fee-for-service and the HealthChoices managed-care plans, does not cover GLP-1 receptor agonists for the treatment of overweight or obesity 1.
Preferred agents (Ozempic, Rybelsus, Trulicity, Victoza) and non-preferred agents (Wegovy, Zepbound, Mounjaro) are covered only for other FDA-approved or medically accepted indications: type 2 diabetes; reduction of major adverse cardiovascular events in patients with a BMI of 27 or higher and a prior heart attack, stroke, or peripheral artery disease; noncirrhotic MASH with stage F2 or F3 fibrosis; or moderate-to-severe obstructive sleep apnea with a BMI of 35 or higher 12.
Saxenda (liraglutide) is not covered for any indication, and every GLP-1 prescription needs prior authorization whether or not it sits on the preferred drug list 12. This policy took effect March 2, 2026, replacing the version in place since January 1, 2026 1.
Astra's price in Pennsylvania is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose.
Median household income in Pennsylvania is $77,545 (ACS 2024 1-year estimate, MOE ±$816) 5. We publish one national price rather than a state-by-state one, so nothing about that figure changes what a Pennsylvanian pays us.
Not yet verified. Pennsylvania-specific telehealth prescribing rules, including in-person exam requirements and any limits on questionnaire-only intake, were not researched in this pass, and this page does not assert them.
Check current requirements with the Pennsylvania State Board of Medicine directly.
Astra is licensed to treat patients in all 50 states, Pennsylvania included, with visits and prescriptions handled entirely by telehealth.
Pennsylvania's population reached 13,078,751 in 2024, and the shape of that growth is unusual: the state added just 61,030 people that year, deaths outnumbered births by 9,311, and essentially all net growth came from migration into the state 4.
Astra treats patients in Pennsylvania through state-licensed physicians.
City-level detail for Pennsylvania.
No, not for weight loss on its own. PA Medical Assistance covers GLP-1 receptor agonists only for other approved uses -- type 2 diabetes, cardiovascular risk reduction in patients with a BMI of 27+ and a prior heart attack, stroke, or PAD, noncirrhotic MASH with advanced fibrosis, or moderate-to-severe sleep apnea with a BMI of 35+ -- and every prescription needs prior authorization. Saxenda isn't covered for any reason. This took effect March 2, 2026.
No. Astra's price is national: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans, whether you're in Allentown, Reading, Philadelphia, or anywhere else in the state -- the same price as every other state we serve.
34.2% of Pennsylvania adults have obesity, and another 34.7% are overweight -- together, 68.9% of the state's adults are above a healthy weight range, per the CDC's 2024 BRFSS survey.
Yes. Astra is licensed to treat patients in all 50 states, including Pennsylvania, with online visits and prescriptions handled entirely by telehealth.
We haven't independently verified Pennsylvania's specific telehealth-prescribing requirements yet -- check with the Pennsylvania State Board of Medicine directly for the current rules.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.